The advent of radiation therapy as a common modality in the treatment and palliation of breast cancer has led to the observation of morphea developing months to years after supervoltage radiation therapy, in and around the site of treatment. We report 2 new cases of morphea at the site of previous supervoltage radiation therapy for breast cancer. The time period between irradiation and onset of morphea in our 2 patients were an atypically long 6.5 years and 32 years, the latter being the longest reported such interval. With conservative treatment, the inflammatory component of the lesions resolved over an approximately 1-year period, leaving residual sclerosis. These patients are compared to those previously reported in the medical literature so as to summarize the range of clinical presentation and course. Recognition of postirradiation morphea is important in distinguishing it from infectious cellulitis, recurrent carcinoma, metastatic carcinoma or development of a second primary carcinoma.

Keywords:
Breast, Fibrosis, Morphea, Radiation therapy, Supervoltage
1.
Dering SB: Modern Radiology in Histological Perspective. Springfield, Thomas, 1960, p 105.
2.
Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA: Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1990;265:3293–3295.
3.
Liegner LM, Michaud NJ: Skin and subcutaneous reactions induced by supervoltage irradiation. Am J Roentgenol 1961;85:533–549.
4.
Davis DA, Cohen PR, McNeese MD, Duvic M: Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma. J Am Acad Dermatol 1996;35:923–927.
5.
Winkelmann RK, Graso GL, Quimby SR, Connolly SM: Pseudoscleromatous panniculitis after irradiation: An unusual complication of megavoltage treatment of breast cancer. Mayo Clin Proc 1993;68:122–127.
6.
Trattner A, Figer A, David M, Lurie H, Sandbank M: Circumscribed scleroderma induced by postlumpectomy radiation therapy. Cancer 1991;68:2131–2133.
7.
Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JAA: Post-irradiation morphea. Br J Dermatol 1989;120:831–835.
8.
Forbes AM, Woodrow JC, Verbov JL, Groham RM: Carcinoma of the breast and scleroderma: Four further cases and a literature review. Br J Rheumatol 1989;29:65–69.
9.
Smith KJ, Yeager J, Skelton HG: Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma (letter, comment). J Am Acad Dermatol 1997;37:806–807.
10.
Gollob MH, Dekoven JG, Bell MJ, Assaad D, Rao J: Postradiation morphea. J Rheumatol 1998;25:2267–2269.
11.
Clarke D, Martinez A, Cox RD: Analysis of cosmetic results and complications in patients with Stage I and II breast cancer treated by biopsy and irradiation. Int J Radiat Oncol Biol Phys 1983;9:533–549.
12.
Bentzen SM, Thames HD, Overgaard M: Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single follow-up clinical study. Radiother Oncol 1989; 15:267–274.
13.
Archambeau JO, Pezner R, Wasserman T: Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 1995;31:1171– 1185.
14.
James WD, Odom RB: Late subcutaneous fibrosis following megavoltage radiotherapy. J Am Acad Dermatol 1980;3:616–618.
15.
Harrison GO, Elliott RL: Scleroderma of the breast: Light and electron microscopy study. Am Surg 1987;9:528–531.
16.
Peterson LS, Nelson AM, Su WPD, Mason T, O’Fallon WM, Gabriel SE: The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 1997;24:73– 80.
17.
Greenberg GS, Falanga V: Localized cutaneous sclerosis; in Sontheimer RD, Provost TT (eds): Cutaneous Manifestations of Rheumatic Diseases. Baltimore, Williams & Wilkins, 1996, pp 141–155.
18.
Lee EB, Anhalt GJ, Voorhees JJ, Diaz LA: Pathogenesis of scleroderma: Current concepts. Int J Dermatol 1984;23:85–89.
19.
Charley MR, Deng JS: Murine models of graft-versus-host disease with features of scleroderma. Immunol Ser 1989;46:625–640.
20.
Artlett CM, Smith JB, Jimenez SA: Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998;338:1186–1191.
21.
Smith EA, LeRoy EC: A possible role for transforming growth factor in systemic sclerosis. J Invest Dermatol 1990;95:1255–1275.
22.
Kikuchi K, Kadono T, Ihn H, Sato S, Igarashi A, Nakagawa H, Tamaki K, Takehara K: Growth regulation in scleroderma fibroblasts: Increased response to transforming growth factor-beta 1. J Invest Dermatol 1995;105:128– 132.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.